Skip to main content

Creon 20 News

Pancreatic Enzyme Therapy Linked to Drop in Pediatric Acute Pancreatitis

TUESDAY, April 16, 2024 – Use of pancreatic enzyme therapy (PERT) is associated with a reduction in the incidence rate of acute pancreatitis (AP) among children with pancreatic sufficient acute...

Abbott Receives FDA Approval for Creon (pancrelipase) Infant-Specific Dosage for Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

First infant-specific dosage strength now approved by the FDA ABBOTT PARK, Ill., June 14, 2011 /PRNewswire/ – Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved an...

Abbott Receives FDA Approval for Creon to Include Dosing Information for Patients With Chronic Pancreatitis and Pancreatectomy

ABBOTT PARK, Ill.., May 3 /PRNewswire-FirstCall/ – Abbott (NYSE:ABT) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for CREON® ...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Chronic Pancreatitis, Cystic Fibrosis

Related drug support groups

Creon

Creon 20 patient information at Drugs.com